Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival

Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study

(2021) Christine H. Chung et al.   Cancers

Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma

(2021) Risa Motai et al.   International Journal of Clinical Oncology

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study

(2020) Viktor Grünwald et al.   ORAL ONCOLOGY

Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma

(2019) Daniel L. Faden et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

(2019) Robert L. Ferris et al.   CLINICAL CANCER RESEARCH

Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting

(2019) Roberta Depenni et al.   EUROPEAN JOURNAL OF CANCER

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial

(2019) Douglas Adkins et al.   LANCET ONCOLOGY

Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

(2019) Khalil Saleh et al.   EUROPEAN JOURNAL OF CANCER

Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions

(2019) Hsiang‐Fong Kao et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

(2019) Jason Chia‐Hsun Hsieh et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing

(2018) Patrick H. Lizotte et al.   Cancer Immunology Research

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC

(2018) Weimin Lin et al.   Frontiers in Oncology

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group

(2017) Shanthi Marur et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy

(2017) Teresa Magnes et al.   PLoS One

Increased PD-1 + and TIM-3 + TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients

(2017) Hyun-Bae Jie et al.   Cancer Immunology Research

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

CTLA-4+Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis

(2015) Hyun-Bae Jie et al.   CANCER RESEARCH

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial

(2014) J. B. Vermorken et al.   ANNALS OF ONCOLOGY

An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents

(2014) Julien Péron et al.   BMC CANCER

Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution

(2014) Ramon Andrade de Mello et al.   PLoS One

TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells

(2013) Ryan M. Stephenson et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients

(2013) R. M. Srivastava et al.   CLINICAL CANCER RESEARCH

Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

(2009) L. Licitra et al.   ANNALS OF ONCOLOGY

Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial

(2009) Merrill S. Kies et al.   JOURNAL OF CLINICAL ONCOLOGY

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE